Ranbaxy Laboratories Ltd. Wednesday said it has settled all manufacturing issues with the U.S. health regulator, an agreement that could pave the way for parent Daiichi Sankyo Co. to finally benefit from its pricey Indian acquisition.
Ranbaxy settles with U.S. regulator
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.
Recommended for You